MCS110: Clinical Trials

5 trials of MCS110, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Terminated 1
Phase 13Completed 2, Terminated 1

Follow MCS110: new trials by email Literature Review of MCS110 trials Research Report on MCS110

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
MCS110, Dabrafenib, Trametinib - Melanoma
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute62018-09-102024-07-31
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
MCS110, PDR001 - Triple Negative Breast Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals1412016-06-292021-08-11
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
MCS110, carboplatin, gemcitabine - Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Phase 2CompletedNovartis Pharmaceuticals502015-08-102021-06-21
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
MCS110, Placebo - Pigmented Villonodular Synovitis, PVNS
Phase 2CompletedNovartis Pharmaceuticals362012-04-232021-01-05
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
MCS110 - Prostate Cancer, Bone Metastases
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals32008-09-012020-12-19

Conditions studied

Melanoma (2)  ·  Endometrial Neoplasms (1)  ·  Giant Cell Tumor of Tendon Sheath (1)  ·  Pancreatic Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Synovitis, Pigmented Villonodular (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  Dana-Farber Cancer Institute (1)

Countries

United States (5)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Hong Kong (2)  ·  Italy (2)  ·  South Korea (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Austria (1)  ·  Finland (1)  ·  Japan (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)

Top investigators

Elizabeth I Buchbinder, MD (1)

Results publications

PMID 38721402

NIH funding

2015 (1), 2016 (1)